Intended for healthcare professionals

  1. Education
  2. Combination therapy...
  3. Combination therapy for painful diabetic neuropathy is safe and effective
Practice NIHR Alerts

Combination therapy for painful diabetic neuropathy is safe and effective

BMJ 2023; 381 doi: https://doi.org/10.1136/bmj.p866 (Published 21 April 2023) Cite this as: BMJ 2023;381:p866
  1. Helen Saul, editor in chief1,
  2. Brendan Deeney, science writer1,
  3. Candace Imison, deputy director of dissemination and knowledge mobilisation1,
  4. Solomon Tesfaye, honorary professor of diabetic medicine2
  1. 1NIHR Evidence, Twickenham, UK
  2. 2University of Sheffield, Sheffield, UK
  1. Correspondence to H Saul evidence{at}nihr.ac.uk

The study

Tesfaye S, Sloan G, Petrie J, et al. Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomised crossover trial. Lancet 2022;400:680-90.

To read the full NIHR Alert, go to: https://evidence.nihr.ac.uk/alert/combination-therapy-for-painful-diabetic-neuropathy-is-safe-and-effective/

Footnotes

  • Competing interests: The BMJ has judged that there are no disqualifying financial ties to commercial companies. The authors declare the following other interests: none.

  • Further details of The BMJ policy on financial interests are here: https://www.bmj.com/about-bmj/resources-authors/forms-policies-and-checklists/declaration-competing-interests.

  • All authors contributed to the development and review of this summary, as part of the wider NIHR Alerts editorial team.

  • More summaries of NIHR research are available at: https://evidence.nihr.ac.uk/alerts/.

  • Disclaimer: NIHR Alerts are owned by the Department of Health and Social Care and are made available to The BMJ under licence. NIHR Alerts report and comment on health and social care research but do not offer any endorsement of the research. The NIHR assumes no responsibility or liability arising from any error or omission or from the use of any information contained in NIHR Alerts.

  • Permission to reuse these articles should be directed to NIHRAlerts@nihr.ac.uk.

View Full Text

Log in

Log in through your institution

Subscribe

* For online subscription

Buy this article

Back to top